Praxis Precision Medicines/PRAX

$46.12

2.01%
-
1D1W1MYTD1YMAX

About Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.

Ticker

PRAX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Marcio Souza

Employees

82

Headquarters

Boston, United States

PRAX Metrics

BasicAdvanced
$754M
Market cap
-
P/E ratio
-$15.91
EPS
2.78
Beta
-
Dividend rate
$754M
2.78393
$67.21
$12.45
254K
11.27
-71.89%
-85.25%
-83.56%
343.561
2.544
3.283
221.38%
72.47%

What the Analysts think about PRAX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
192.71% upside
High $270.00
Low $40.00
$46.12
Current price
$135.00
Average price target

PRAX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-9,875% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-20%
Net income
-$40M
47.39%
Profit margin
-9,875%
84.24%

PRAX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 36.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$7.35
-$2.70
-$2.97
-$2.84
-
Expected
-$9.83
-$5.25
-$3.19
-$2.08
-$2.40
Surprise
-25.24%
-48.57%
-6.75%
36.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Praxis Precision Medicines stock?

Praxis Precision Medicines (PRAX) has a market cap of $754M as of May 29, 2024.

What is the P/E ratio for Praxis Precision Medicines stock?

The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of May 29, 2024.

Does Praxis Precision Medicines stock pay dividends?

No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Praxis Precision Medicines dividend payment date?

Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Praxis Precision Medicines?

Praxis Precision Medicines (PRAX) has a beta rating of 2.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Praxis Precision Medicines stock price target?

The target price for Praxis Precision Medicines (PRAX) stock is $135, which is 192.71% above the current price of $46.12. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Praxis Precision Medicines stock

Buy or sell Praxis Precision Medicines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing